

Boost Seminar
December 6th 2017

Navigating the Shifting Currents of U.S. Biotech and Pharmaceutical Patent Law



Margaret (Peg) Bolce Brivanlou, PhD

Partner

Intellectual Property Counseling/Intellectual Property,
Patent, Trademark and Copyright Litigation
King & Spalding

Peg Brivanlou specializes in patent prosecution, client counseling, due diligence and patent litigation. As a Partner in our Intellectual Property, Patent, Trademark and Copyright Litigation practice, Peg represents clients in the biotechnology and pharmaceutical industries, and investment funds in a variety of intellectual property matters.

With a focus on biologics and small molecule therapeutics, Peg counsels clients regarding immunotherapeutics, cell-based assays and therapies, genomics, bioinformatics, vaccines and small molecule pharmaceuticals. She is experienced in developing patent portfolios, particularly relating to biologics, antibody therapeutics and diagnostics. She also conducts patent invalidity, freedom-to-operate analyses and pre-litigation investigations, including for pre-Hatch-Waxman litigation.

In addition, Peg represents clients on the intellectual property aspects of a wide range of transactions, from technology transfer and out-licensing to multi-million-dollar asset purchases and financings. She conducts due diligence, and negotiates licensing and purchase agreements as well as disclosure documents in connection with public and private financings.

Presenting to conferences and in-house counsel, Peg is a frequent speaker on a variety of patent issues.

Credentials

EDUCATION

A.B., Cornell University, magna cum laude

J.D., Harvard University, cum laude

Ph.D., University of California-Berkeley

ADMISSIONS

U.S. Patent and Trademark Office

New York

ASSOCIATIONS

New York State Bar Association

New York Intellectual Property Law Association

LANGUAGES

French

Matters

- Primary intellectual property counsel to **a private investment fund** in connection with significant royalty stream acquisitions and financings.
- Represents **a private biotechnology company** in developing patent portfolio relating to immunotherapeutics.
- Represents **a major pharmaceutical company** in patent prosecution and counseling relating to small molecule pharmaceuticals, including approved products and products in late stage clinical trials, for cardiovascular indications.
- Represents **a foreign pharmaceutical firm** in patent prosecution and counseling relating to RNAi therapeutics.
- Represented **a major pharmaceutical company and private biotechnology companies** in administrative and court challenges against the USPTO relating to patent term adjustment calculations.

Insights

ARTICLE

2017-06-15

High Court's Superficial Analysis In Biosimilars Ruling

CLIENT ALERT

2017-06-13

The Age of Competition

ARTICLE

2017-06-12

Clarity From Chaos

THOUGHT LEADERSHIP

2017-02-27

U.S. PTO Highlights Patent Paper Co-Authored by Kenneth Sonnenfeld

CLIENT ALERT

2016-05-11

Patentable Subject Matter in the Life Sciences: New USPTO Guidance Impacts Diagnostics Methods and Natural Products

THOUGHT LEADERSHIP

2016-03-06

Peg Brivanlou to Co-Host Women in Licensing-DC Meeting

Events

CONFERENCE

2017-09-07

Medical Device Summit 2017

CONFERENCE

2017-06-08

Managing IP's International Women's Leadership Forum

CONFERENCE

2016-11-15

9th Annual King & Spalding Pharmaceutical University

CONFERENCE

2015-10-28

ChIPs Women in IP Global Summit 2015, Tenth Anniversary Celebration

WEBINAR

2015-09-10

All Trees, No Forest? Making Sense of Recent Developments in Life Sciences Patent Law

News

CASES & DEALS

2017-08-09

King & Spalding Advises Dermira on Worldwide Licensing Agreement with Roche

RECOGNITION

2017-06-20

Chambers Honors King & Spalding's Women in IP Group With 'Most Innovative Women's Networking Group' Award